Drostanolone
Drostanolone was used in breast-cancer treatment. Those oncology studies do not establish a safe bodybuilding regimen or a predictable “dry” look.
Anabolic-androgenic steroid
- Also called Masteron
- Historical propionate medicine
What is Masteron, and which drug was used medically?
Masteron refers to drostanolone, historically called dromostanolone. The old oncology product used the propionate ester.
A product labeled enanthate is a different formulation. It cannot inherit the clinical history or clearance assumptions of the former propionate medicine.
Masteril · historical comparative trial
Historical comparative trial
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde. PMID 1242823.
Drostanolone propionate was compared with different treatments in premenopausal, perimenopausal and postmenopausal breast-cancer groups. The reported direction of response differed with the comparator and group.
The abstract lacks group denominators. Its broad “safe” conclusion cannot establish modern long-term safety or a cosmetic-use benefit.
Read the original sourceFDA · Drolban product history
FDA application review
FDA proprietary-name review, 2017, appendix on discontinued names.
FDA records Drolban as discontinued with no generic equivalent and cites withdrawal of NDA 012936 effective March 2, 1994.
The document establishes historical US product status, not a worldwide market survey.
Read the original sourceHuman evidence · unresolved questions
Evidence summary
PubMed, primary journal records, and product records.
The cited sources include historical oncology comparisons and human metabolite analysis. They do not establish a controlled cosmetic-hardness result, a modern performance-use safety profile or a systemic half-life for an underground enanthate formulation.
Was it actually studied in people?
Yes. Its human clinical history includes older breast-cancer studies with controlled comparisons.
A 91-patient study compared drostanolone with other hormonal treatments and did not find a difference in efficacy. Later assessments included added chemotherapy, so the pooled remission rates cannot be attributed to drostanolone alone.
Advanced breast cancer · controlled comparison
Historical controlled clinical trial
Onkologie. PMID 362297.
A 91-patient controlled study compared drostanolone, nandrolone and testololactone. It found no efficacy difference among the groups. Cyclophosphamide was added during the later treatment interval.
The abstract’s average remission rates pool treatments and are not drostanolone-specific.
Read the original sourceDoes historical cancer use validate a bodybuilding claim?
No. Tumor response in people with advanced cancer is a different outcome from muscle gain, fat loss or visual hardness in healthy users. The trials used different comparators and medical populations.
Masteril · historical comparative trial
Historical comparative trial
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde. PMID 1242823.
Drostanolone propionate was compared with different treatments in premenopausal, perimenopausal and postmenopausal breast-cancer groups. The reported direction of response differed with the comparator and group.
The abstract lacks group denominators. Its broad “safe” conclusion cannot establish modern long-term safety or a cosmetic-use benefit.
Read the original sourceHuman evidence · unresolved questions
Evidence summary
PubMed, primary journal records, and product records.
The cited sources include historical oncology comparisons and human metabolite analysis. They do not establish a controlled cosmetic-hardness result, a modern performance-use safety profile or a systemic half-life for an underground enanthate formulation.
Does it produce a proven dry or hard look?
The cited clinical studies did not measure that cosmetic outcome. A reputation or chemical mechanism cannot supply its expected size, likelihood or safety.
An old cancer-treatment role also does not establish that drostanolone treats gynecomastia or replaces an aromatase inhibitor in a self-directed drug combination.
Human evidence · unresolved questions
Evidence summary
PubMed, primary journal records, and product records.
The cited sources include historical oncology comparisons and human metabolite analysis. They do not establish a controlled cosmetic-hardness result, a modern performance-use safety profile or a systemic half-life for an underground enanthate formulation.
Advanced breast cancer · controlled comparison
Historical controlled clinical trial
Onkologie. PMID 362297.
A 91-patient controlled study compared drostanolone, nandrolone and testololactone. It found no efficacy difference among the groups. Cyclophosphamide was added during the later treatment interval.
The abstract’s average remission rates pool treatments and are not drostanolone-specific.
Read the original sourceWhat side effects are known?
A reliable modern drostanolone-specific adverse-event rate is not established by the cited studies. That gap is not evidence of low risk.
Anabolic-steroid risks include adverse cholesterol changes, acne and other androgenic effects, mood changes and suppression of sperm production. Class data do not provide drostanolone-specific event rates.
FDA · anabolic-steroid risks
Regulatory safety review
US FDA, 2017.
FDA describes serious liver injury, adverse lipids, mood changes, androgenic effects and gonadal suppression associated with anabolic-steroid products. Some reports involved multiple products, preventing attribution to one ingredient.
Class-level risk information does not provide an individual compound’s event rate.
Read the original sourceThe older Masteril abstract’s favorable safety description came from its oncology setting. It cannot establish long-term safety of performance use or a different ester.
Masteril · historical comparative trial
Historical comparative trial
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde. PMID 1242823.
Drostanolone propionate was compared with different treatments in premenopausal, perimenopausal and postmenopausal breast-cancer groups. The reported direction of response differed with the comparator and group.
The abstract lacks group denominators. Its broad “safe” conclusion cannot establish modern long-term safety or a cosmetic-use benefit.
Read the original sourceWhy is an androgen found in old breast-cancer studies?
Hormonal manipulation was used to treat selected advanced breast cancers. Drostanolone propionate was one of the androgen treatments tested.
The oncology trials measured tumor response in selected patients with advanced breast cancer. They did not test other tissues or estrogen-related symptoms.
Masteril · historical comparative trial
Historical comparative trial
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde. PMID 1242823.
Drostanolone propionate was compared with different treatments in premenopausal, perimenopausal and postmenopausal breast-cancer groups. The reported direction of response differed with the comparator and group.
The abstract lacks group denominators. Its broad “safe” conclusion cannot establish modern long-term safety or a cosmetic-use benefit.
Read the original sourceAdvanced breast cancer · controlled comparison
Historical controlled clinical trial
Onkologie. PMID 362297.
A 91-patient controlled study compared drostanolone, nandrolone and testololactone. It found no efficacy difference among the groups. Cyclophosphamide was added during the later treatment interval.
The abstract’s average remission rates pool treatments and are not drostanolone-specific.
Read the original sourceDoes the urine study establish a human half-life?
No. The modern analytical study measures urinary metabolites and detection windows. Those cannot substitute for a blood concentration-time study of the exact formulation.
The human metabolism study reports urinary detection, not a systemic half-life or injection interval for propionate or enanthate products.
Drostanolone metabolism · urine detection
Human analytical metabolism study
Steroids. PMID 26826321.
A study administering drostanolone to one volunteer identified urinary metabolites that could be detected for longer than conventional markers.
A metabolite-detection study does not establish therapeutic efficacy, organ safety or an injection’s systemic half-life.
Read the original sourceHuman evidence · unresolved questions
Evidence summary
PubMed, primary journal records, and product records.
The cited sources include historical oncology comparisons and human metabolite analysis. They do not establish a controlled cosmetic-hardness result, a modern performance-use safety profile or a systemic half-life for an underground enanthate formulation.
What happened to Drolban in the US?
FDA’s application review records withdrawal of Drolban’s approval effective March 2, 1994.
The historical record does not verify a current online product or mean that an enanthate preparation was the approved medicine.
FDA · Drolban product history
FDA application review
FDA proprietary-name review, 2017, appendix on discontinued names.
FDA records Drolban as discontinued with no generic equivalent and cites withdrawal of NDA 012936 effective March 2, 1994.
The document establishes historical US product status, not a worldwide market survey.
Read the original sourceStudies and sources
FDA · Drolban product history
FDA application review
FDA proprietary-name review, 2017, appendix on discontinued names.
FDA records Drolban as discontinued with no generic equivalent and cites withdrawal of NDA 012936 effective March 2, 1994.
The document establishes historical US product status, not a worldwide market survey.
Read the original sourceAdvanced breast cancer · controlled comparison
Historical controlled clinical trial
Onkologie. PMID 362297.
A 91-patient controlled study compared drostanolone, nandrolone and testololactone. It found no efficacy difference among the groups. Cyclophosphamide was added during the later treatment interval.
The abstract’s average remission rates pool treatments and are not drostanolone-specific.
Read the original sourceMasteril · historical comparative trial
Historical comparative trial
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde. PMID 1242823.
Drostanolone propionate was compared with different treatments in premenopausal, perimenopausal and postmenopausal breast-cancer groups. The reported direction of response differed with the comparator and group.
The abstract lacks group denominators. Its broad “safe” conclusion cannot establish modern long-term safety or a cosmetic-use benefit.
Read the original source1963 report · bibliographic record
Historical clinical report
Di Pietro S, Salvadori B. Tumori, 1963. PMID 14027591.
The indexed report concerns advanced breast cancer treated with 2-alpha-methyldihydrotestosterone propionate. PubMed provides no abstract.
The publication supports the historical treatment context but does not provide confirmed numerical outcomes for this summary.
Read the original sourceDrostanolone metabolism · urine detection
Human analytical metabolism study
Steroids. PMID 26826321.
A study administering drostanolone to one volunteer identified urinary metabolites that could be detected for longer than conventional markers.
A metabolite-detection study does not establish therapeutic efficacy, organ safety or an injection’s systemic half-life.
Read the original sourceFDA · anabolic-steroid risks
Regulatory safety review
US FDA, 2017.
FDA describes serious liver injury, adverse lipids, mood changes, androgenic effects and gonadal suppression associated with anabolic-steroid products. Some reports involved multiple products, preventing attribution to one ingredient.
Class-level risk information does not provide an individual compound’s event rate.
Read the original sourceHuman evidence · unresolved questions
Evidence summary
PubMed, primary journal records, and product records.
The cited sources include historical oncology comparisons and human metabolite analysis. They do not establish a controlled cosmetic-hardness result, a modern performance-use safety profile or a systemic half-life for an underground enanthate formulation.
Why is Drostanolone in B tier?
Drostanolone remains B tier for its historical human clinical record. The evidence concerns oncology, with substantial gaps for present-day performance use and product-specific safety.